Skip to content

The efficacy of the Lysophosphatidylcholine for atopic dermatitis with facial acne or folliculitis: A Multicenter, Randomized, Double-blind Trial

The efficacy of the Lysophosphatidylcholine for atopic dermatitis with facial acne or folliculitis: A Multicenter, Randomized, Double-blind Trial - The efficacy of the Lysophosphatidylcholine for atopic dermatitis with facial acne or folliculitis: A Multicenter, Randomized, Double-blind Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026338
Enrollment
40
Registered
2017-02-28
Start date
2017-02-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis facial acne folliculitis

Interventions

Use the test moisturizer containing Lysophosphatidylcholine (LPC-1)in combination with other treatment for 4 weeks. Use the test moisturizer in combination with other treatment for 4 weeks.

Sponsors

Yokohama City University Graduate School of Medicine
Lead Sponsor
Yokohama city university medical center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)AD Patients with mild-to-severe disease severity based on the classification criteria by atopic dermatitis Japanese Dermatological Association. (2)Patients who agree to stop using moisturizers other than test drugs on the face during the research period. (3)Patients who have no problem for walking and answering to questionnaire survey. (4)Patients who agree with the study and provide the written informed consent (consent from a legal guardian in case of under 20 years old) .

Exclusion criteria

Exclusion criteria: (1)Patients who are classified as the most severe atopic dermatitis. (2)Patients who are under treatments of UV therapy or immunosuppressant drugs for atopic dermatitis. (3)Patients who need to start new antihistamines. (4)Patients taking antibiotics. (5)In addition, patients who are inappropriate as subjects defined by doctors.

Design outcomes

Primary

MeasureTime frame
Severity of atopic dermatitis (AD)

Countries

Japan

Contacts

Public ContactMiho Asami

Yokohama City University Graduate School of Medicine Department of Environmental Immuno-Dermatology

dermaycu@yokohama-cu.ac.jp045-787-2675

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026